0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover415.40%IV-60.64%PremiumJul 19, 2024Expiry Date1.51Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6747Delta0.2335Gamma1.42Leverage Ratio-0.0343Theta-0.0007Rho-0.96Eff Leverage0.0013Vega
Esperion Therapeutics Stock Discussion
Esperion, a well-known entity in the biopharmaceutical industry trading under the Nasdaq symbol ESPR, has recently entered into a pivotal financial transaction with OMERS Life Sciences, a prominent investor in the life sciences sector. The essence of this transaction r...
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions(SWKS.US)$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
NEWS
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
The European Commission has approved label updates for NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid/ezetimibe) to treat hypercholesterolemia and reduce cardiovascular risk. This approval is based on the positi...
No comment yet